

*Sanofi India Limited (SIL) declares 8% growth
in net sales for Q4-2024*

Standalone Profit from Operations for Q4-2024 were INR 108 crores

Mumbai, February 27, 2024. The board of Sanofi India Limited (SIL) today approved its standalone and consolidated financial results, for Q4 and year to date ended on December 31st, 2024, after the demerger of its consumer healthcare business effective from June 1st, 2024.

Diabetes portfolio reported double digit growth for Toujeo® and successful launch of Soliqua® reinstating confidence and strength in our comprehensive diabetes portfolio.

The recently announced partnerships for CNS (Central Nervous System) and the CV (Cardiovascular) brands have established their foundation for acceleration, expansion in reach and achievement were as expectation.

The Company was able to increase its operating profit (*) in Q4-2024 by 21% vs Q4-2023. The Profit from Operations for Q4-2024 was at INR 108 crores versus INR 90 crores Q4-2023.

The Company continues to make good progress on its 'India for India' strategy through go-to-market initiatives, improving operating efficiency and promoting innovation.

(*): Operating profit= Revenue from operations – Total expenses

Rodolfo Hrosz

Managing Director, Sanofi India Limited

“In a year of significant transformation for the company, we have successfully brought to market Soliqua® - our best-in-class diabetes drug for the premix segment, which has received encouraging acceptance. Our efforts of reaching more HCPs through partnerships for the Cardiovascular and CNS (Central Nervous System) categories have advanced as planned, with initial promising results. We will continue to focus on driving further improvement in operating efficiencies while expanding the availability of established and innovative products in India.”

Sanofi in India

Present in India for nearly seven decades, Sanofi has earned the trust of customers and stakeholders for its commitment to promoting health. As Sanofi chases the miracles of science to improve people's lives, it continues to engage across the entire health spectrum from prevention with vaccines to wellness, treatment, patient support & capacity building.

Sanofi's India Charitable Access Program (InCAP) is the country's longest running humanitarian program providing free treatment to people afflicted with Lysosomal Storage Disorders. Sanofi conducts clinical trials in India, so that the country can have quicker access to the latest from the company's global pipeline. Sanofi India's world-class manufacturing site in Goa produces for people in India and 60+ other countries. Sanofi has located one of its four global talent hubs in Hyderabad, India, from where wide range of services are provided globally.

Recognized by the 'Top[®] Employers Institute' – a global authority that honours excellence in people practices since 2019, Sanofi's local entities include Sanofi India Limited (SIL - listed entity), and Sanofi Healthcare India Pvt. Ltd. (SHIPL) and Sanofi Consumer Healthcare India Limited (SCHIL). For more information, visit: www.sanofi.in and www.sanofiindialtd.com, [LinkedIn](#) and [Twitter](#).

Media Relations

Vinifer Gandhi | vinifer.gandhi@sanofi.com